ADAM22 anticorps (Extracellular, N-Term)

N° du produit ABIN7042881

Cet anticorps anti-ADAM22 Polyclonal Lapin (ABIN7042881) détecte spécifiquement ADAM22 dans WB, IHC et IF. L’anticorps est réactif avec des échantillons de Souris.

Aperçu rapide pour ADAM22 anticorps (Extracellular, N-Term) (ABIN7042881)

Antigène: ADAM22 (ADAM Metallopeptidase Domain 22 (ADAM22))

Reactivité: Souris

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp ADAM22 est non-conjugé

Application: Western Blotting (WB), Immunohistochemistry (IHC), Immunofluorescence (IF)

Détail du produit anti-ADAM22 anticorps

Épitope: AA 715-729, Extracellular, N-Term

Fonction: A Rabbit Polyclonal Antibody to ADAM22

Réactivité croisée: Humain, Souris, Rat

Homologie: Rat,human - identical

Attributs du produit: Anti-ADAM22 (extracellular) Antibody (ABIN7042881, ABIN7044724 and ABIN7044725) is a highly specific antibody directed against an epitope of the mouse protein. The antibody can be used in western blot and immunohistochemistry applications. The antibody recognizes an extracellular epitope and can potentially be used for detecting the protein in living cells. It has been designed to recognize ADAM22 from rat, mouse, and human samples.

Purification: Affinity purified on immobilized antigen.

Immunogène: (C)HNDDAKTGITLSGNG, corresponding to amino acid residues 715-729 of mouse ADAM22

Isotype: IgG

Information d'application

Indications d'application:

WB: 1:200

FC: The optimal concentration should be determined by the user

ICC: The optimal concentration should be determined by the user

IHC: 1:200

IP: The optimal concentration should be determined by the user

Commentaires:

Negative Control: (ABIN7234619)

Blocking Peptide: (ABIN7234619)

Restrictions: For Research Use only

Stockage

Format: Lyophilized

Reconstitution: 25 μL, 50 μL or 0.2 mL double distilled water (DDW), depending on the sample size.

Concentration: 0.8 mg/mL

Buffer: PBS pH 7.4, 1 % BSA with 0.05 % sodium azide

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: -20 °C

Stockage commentaire: The antibody ships as a lyophilized powder at room temperature. Upon arrival, it should be stored at -20°C

Détails sur ADAM22

Antigène: ADAM22 (ADAM Metallopeptidase Domain 22 (ADAM22))

Autre désignation: ADAM22

Sujet:

Synonyms: Disintegrin and metalloproteinase domain-containing protein 22, ADAM metallopeptidase domain 22, MDC2

Description: ADAMs (a disintegrin and metalloproteinases) are multi-domain transmembrane glycoproteins with diverse roles in physiology and disease. Notably, 8 of 21 ADAMs lack functional metalloproteinase domains and are implicated in protein-protein interactions instead of membrane protein ectodomain shedding.ADAM22 is a non-proteinase which acts as a post synaptic receptor for the secreted neurotransmission modulator LGI-1 at neural synapses. ADAM22 is a compact four-leaf clover with the metalloproteinase-like domain (Domain M) held in the concave face of a rigid module formed by the disintegrin (Domain D), cysteine-rich (Domain C), and epidermal growth factor-like domains (Domain E). The largest domain in the four-leaf clover, domain M, is distal to the cell membrane. Following domain M, domain D and domain C zigzag to domain E in a compact, but not extended fashion. A 15-amino acid linker, leads the C terminus of domain E to the membrane. The loss of metalloproteinase activity is ensured by the absence of critical catalytic residues, the filling of the substrate groove, and the steric hindrance by the cysteine-rich domain. The extracellular domain of ADAM22 interacts with LGI-1, whereas its cytoplasmic PDZ-binding motif recruits PSD-95. The link of ADAM22 and LGI-1 to AMPA receptors establishes their roles in glutamate neurotransmission1.Mutations that impair LGI-1 binding to ADAM22 are implicated in the pathogenesis of Autosomal dominant lateral temporal epilepsy (ADTLE), a focal epilepsy syndrome characterized by focal seizures with prominent auditory or aphasic symptoms, normal magnetic resonance imaging, and usually benign evolution2.

ID gène: 11496

NCBI Accession: NM_021723

UniProt: Q9R1V6